Research & Publications

Summary

This study examined how the timing of starting a specific COPD treatment affects the risk of future exacerbations and serious cardiopulmonary (CP) events. Researchers followed 17,613 COPD patients aged 40 and older, all of whom had a history of significant exacerbations but had never used single inhaler triple therapy (SITT) before. Triple therapy refers to the combination of three medications in one inhaler: budesonide (a corticosteroid that reduces inflammation), glycopyrronium (a long-acting muscarinic antagonist that helps open the airways), and formoterol fumarate (a long-acting beta agonist that helps relax the muscles around the airways). Patients were divided into three groups based on how quickly they started treatment with this combination therapy (BGF) after their initial exacerbation: within 30 days (prompt), between 31 and 180 days (delayed), and between 181 and 365 days (very delayed).

The key findings showed that starting treatment earlier led to fewer future exacerbations and severe CP events. For example, the annual rate of exacerbations per person was 1.35 in the prompt group, compared to 1.77 and 1.98 in the delayed and very delayed groups, respectively. Severe CP event rates were also lowest in the prompt group at 0.34 per person/year, compared to 0.39 in the other groups.

Why this matters

This research showed that earlier initiation of triple therapy (BGF) after a COPD exacerbation was associated with reduced rates of future exacerbations and serious cardiopulmonary events. This study reinforces the need for proactive disease management strategies that prioritize early therapeutic intervention to optimize patient outcomes. Further research is needed to refine COPD management strategies that prioritize early treatment.